TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo

STAT3 operates in both cancer cells and tumor-associated immune cells to promote cancer progression. As a transcription factor, it is a highly desirable but difficult target for pharmacologic inhibition. We have recently shown that the TLR9 agonists CpG oligonucleotides can be used for targeted siRN...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zhang, Qifang, Hossain, Dewan Md Sakib, Nechaev, Sergey, Kozlowska, Anna, Zhang, Wang, Liu, Yong, Kowolik, Claudia M., Swiderski, Piotr, Rossi, John J., Forman, Stephen, Pal, Sumanta, Bhatia, Ravi, Raubitschek, Andrew, Yu, Hua, Kortylewski, Marcin
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2013
Assuntos:
Gene Therapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3578952/
https://ncbi.nlm.nih.gov/pubmed/23287859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-07-442590
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados